Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Pannexin 1 – a novel target for pediatric orphan epilepsy

Project description

Targeted therapy for drug-resistant paediatric epilepsy

Childhood epilepsy is a neurological disorder characterised by recurrent seizures due to abnormal electrical activity in the brain. Early diagnosis and treatment are crucial to managing seizures and minimising the impact on cognitive and developmental growth. The EIC-funded PANNEXIN project focuses on a novel drug that targets Pannexin 1, a transmembrane protein implicated in the intercellular communication between the nerve system and other tissues. Various neurological disorders including epilepsy have been associated with activated Pannexin 1, so it has emerged as a potential therapeutic target. The team has generated promising preclinical data and aims to adapt the drug for children as young as six months and especially for resistant cases.

Objective

Epilepsy is a group of syndromes with high unmet medical need, especially in children as frequent seizures affect the immature brain and its development. In some orphan syndromes, drug resistance is 70% with dramatic consequences for patients and their families. Novel treatments must prevent the negative effects of seizures, but also minimize off-target effects on brain development and cognitive functions. Our solution is the specific blockade of the activated form of the Pannexin 1 (Panx1) channel using a reformulated form of probenecid: PTI5803. This compound, a first-in-class drug, inhibits seizures preclinically in >80% of cases without hampering cognitive functions. Designed to be adapted to children (from 6 months of age) and to improve the bioavailability, PTI5803 is a highly specific breakthrough product to counteract the pathological activation of Panx1 in patients with an ultra-resistant orphan epilepsy, with the potential to disrupt the market of paediatric epilepsy.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

PANNTHERAPI
Net EU contribution
€ 2 499 500,00
Address
10 RUE DESCARTES
30000 NIMES
France
SME
Yes
Region
Occitanie Languedoc-Roussillon Gard
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 078 906,00